In gastric cancer, through inducing macrophages and PD-L1 to participate in the immunosuppression of the tumor microenvironment, CXCL8 inhibitors could trigger the anti-tumor response, which could provide potential therapeutic effects for gastric cancer patients 29. This evidence concerns the gene CD274 and gastric cancer.